Research Article
Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study
Table 3
Adverse effect profile of induction (TPF + N) and concurrent chemoradiation (T: docetaxel; P, cisplatin; F-5 FU, N-nimotuzumab).
| Adverse effects | N = 20 |
| Nausea/vomiting | Grade I | 4 (20%) | Grade II | 6 (30%) | Grade III | 2 (10%) | Grade IV | 3 (15%) |
| Mucositis | Grade I | 8 (40%) | Grade II | 2 (10%) | Grade III | 4 (20%) | Grade IV | 3 (15%) |
| Rash | Grade I | 2 (10%) |
| Fatigue | Grade I | 7 (35%) | Grade II | 4 (20%) | Grade III | 1 (5%) |
| Diarrhea | Grade 1 | 5 (25%) | Grade II | 3 (15%) |
| Neutropenia | Grade I | 5 (25%) | Grade II | 7 (35%) | Grade III | 3 (15%) | Grade IV | 5 (25%) |
| Neuropathy | Grade I | 4 (20%) | Grade II | 2 (10%) | Grade III | 2 (10%) |
|
|